الملخص
The hunt for an effective vaccine against malaria still continues. Several new target antigens as candidates for vaccine design are being explored and tested for their efficacy. In the present study the sera from mice immunized with 24,000 × g fraction of Plasmodium berghei has been used to identify highly immunogenic blood stage antigens. The protective antibodies present in immune sera were covalently immobilized on CNBr activated sepharose 4B and used for affinity chromatography purification of antigens present in blood stages of P. berghei. Two polypeptides of 66 and 43 kDa molecular weights proved to be highly immunogenic. They exhibited a strong humoral immune response in mice as evident by high titres in ELISA and IFA. Protective immunity by these two antigens was apparent by in vivo and in vitro studies. These two proteins could further be analysed and used as antigens in malaria vaccine design.
الموضوعات
Animals , Histocompatibility Antigens Class II/blood , Humans , Immunity, Humoral/immunology , Immunization , Malaria/blood , Malaria/parasitology , Malaria/prevention & control , Malaria Vaccines/immunology , Mice , Plasmodium berghei/immunology , Plasmodium berghei/pathogenicityالملخص
Plasmodium vivax infects human erythrocytes through a major pathway that requires interaction between an apical parasite protein, the Duffy binding protein (PvDBP) and its receptor on reticulocytes, the Duffy antigen/receptor for chemokines (DARC). The importance of the interaction between PvDBP (region II, DBPII) and DARC to P. vivax infection has motivated our malaria research group at Oswaldo Cruz Foundation (state of Minas Gerais, Brazil) to conduct a number of immunoepidemiological studies to characterise the naturally acquired immunity to PvDBP in populations living in the Amazon rainforest. In this review, we provide an update on the immunology and molecular epidemiology of PvDBP in the Brazilian Amazon - an area of markedly unstable malaria transmission - and compare it with data from other parts of Latin America, as well as Asia and Oceania.
الموضوعات
Humans , Antigens, Protozoan/immunology , Malaria Vaccines/immunology , Malaria, Vivax/prevention & control , Plasmodium vivax/immunology , Protozoan Proteins/immunology , Receptors, Cell Surface/immunology , Antibodies, Protozoan/blood , Antigens, Protozoan/chemistry , Brazil , Enzyme-Linked Immunosorbent Assay , Geography, Medical , Protozoan Proteins/chemistry , Receptors, Cell Surface/chemistryالملخص
Animal models have a long history of being useful tools, not only to test and select vaccines, but also to help understand the elaborate details of the immune response that follows infection. Different models have been extensively used to investigate putative immunological correlates of protection against parasitic diseases that are important to reach a successful vaccine. The greatest challenge has been the improvement and adaptation of these models to reflect the reality of human disease and the screening of vaccine candidates capable of overcoming the challenge of natural transmission. This review will discuss the advantages and challenges of using experimental animal models for vaccine development and how the knowledge achieved can be extrapolated to human disease by looking into two important parasitic diseases: malaria and leishmaniasis.
الموضوعات
Animals , Humans , Leishmaniasis Vaccines/immunology , Leishmaniasis, Cutaneous/prevention & control , Leishmaniasis, Visceral/prevention & control , Malaria Vaccines/immunology , Malaria/prevention & control , Antibody Formation/immunology , Antigens, Protozoan/immunology , Disease Models, Animal , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Visceral/immunology , Malaria/immunologyالملخص
Recently, we described the improved immunogenicity of new malaria vaccine candidates based on the expression of fusion proteins containing immunodominant epitopes of merozoites and Salmonella enterica serovar Typhimurium flagellin (FliC) protein as an innate immune agonist. Here, we tested whether a similar strategy, based on an immunodominant B-cell epitope from malaria sporozoites, could also generate immunogenic fusion polypeptides. A recombinant His6-tagged FliC protein containing the C-terminal repeat regions of the VK210 variant of Plasmodium vivax circumsporozoite (CS) protein was constructed. This recombinant protein was successfully expressed in Escherichia coli as soluble protein and was purified by affinity to Ni-agarose beads followed by ion exchange chromatography. A monoclonal antibody specific for the CS protein of P. vivax sporozoites (VK210) was able to recognise the purified protein. C57BL/6 mice subcutaneously immunised with the recombinant fusion protein in the absence of any conventional adjuvant developed protein-specific systemic antibody responses. However, in mice genetically deficient in expression of TLR5, this immune response was extremely low. These results extend our previous observations concerning the immunogenicity of these recombinant fusion proteins and provide evidence that the main mechanism responsible for this immune activation involves interactions with TLR5, which has not previously been demonstrated for any recombinant FliC fusion protein.
الموضوعات
Animals , Mice , Flagellin/immunology , Immunodominant Epitopes/immunology , Malaria Vaccines/immunology , Malaria, Vivax , Plasmodium falciparum/immunology , Recombinant Fusion Proteins/immunology , Salmonella typhimurium/immunology , Antibodies, Protozoan/immunology , Epitopes, B-Lymphocyte/immunology , Epitopes, B-Lymphocyte , Escherichia coli Proteins/immunology , Flagellin , Immunodominant Epitopes , Malaria Vaccines , Malaria, Vivax/immunology , Protozoan Proteins/immunology , Protozoan Proteins , Recombinant Fusion Proteins , Salmonella typhimurium , /immunologyالملخص
CD8+ T cells against malaria liver stages represent a major protective immune mechanism against infection. Following induction in the peripheral lymph nodes by dendritic cells (DCs), these CD8+ T cells migrate to the liver and eliminate parasite infected hepatocytes. The processing and presentation of sporozoite antigen requires TAP mediated transport of major histocompatibility complex class I epitopes to the endoplasmic reticulum. Importantly, in DCs this process is also dependent on endosome-mediated cross presentation while this mechanism is not required for epitope presentation on hepatocytes. Protective CD8+ T cell responses are strongly dependent on the presence of CD4+ T cells and the capacity of sporozoite antigen to persist for a prolonged period of time. While human trials with subunit vaccines capable of inducing antibodies and CD4+ T cell responses have yielded encouraging results, an effective anti-malaria vaccine will likely require vaccine constructs designed to induce protective CD8+ T cells against malaria liver stages.
الموضوعات
Animals , Humans , Mice , Antigens, Protozoan/immunology , /immunology , Hepatocytes , Liver , Malaria/immunology , /immunology , Epitopes/immunology , Malaria Vaccines/immunology , Malaria , Malariaالملخص
Plasmodium vivax is the most prevalent malaria parasite on the American continent. It generates a global burden of 80-100 million cases annually and represents a tremendous public health problem, particularly in the American and Asian continents. A malaria vaccine would be considered the most cost-effective measure against this vector-borne disease and it would contribute to a reduction in malaria cases and to eventual eradication. Although significant progress has been achieved in the search for Plasmodium falciparum antigens that could be used in a vaccine, limited progress has been made in the search for P. vivax components that might be eligible for vaccine development. This is primarily due to the lack of in vitro cultures to serve as an antigen source and to inadequate funding. While the most advanced P. falciparum vaccine candidate is currently being tested in Phase III trials in Africa, the most advanced P. vivax candidates have only advanced to Phase I trials. Herein, we describe the overall strategy and progress in P. vivax vaccine research, from antigen discovery to preclinical and clinical development and we discuss the regional potential of Latin America to develop a comprehensive platform for vaccine development.
الموضوعات
Animals , Humans , Antigens, Protozoan/immunology , Malaria Vaccines/immunology , Malaria, Vivax , Plasmodium vivax/immunology , Clinical Trials as Topic , Latin America , Malaria, Vivax/immunology , Protozoan Proteins/immunology , Receptors, Cell Surface/immunologyالملخص
The lack of immunogenicity of most malaria antigens and the complex immune responses required for achieving protective immunity against this infectious disease have traditionally hampered the development of an efficient human malaria vaccine. The current boom in development of recombinant viral vectors and their use in prime-boost protocols that result in enhanced immune outcomes have increased the number of malaria vaccine candidates that access pre-clinical and clinical trials. In the frontline, adenoviruses and poxviruses seem to be giving the best immunization results in experimental animals and their mutual combination, or their combination with recombinant proteins (formulated in adjuvants and given in sequence or being given as protein/virus admixtures), has been shown to reach unprecedented levels of anti-malaria immunity that predictably will be somehow reproduced in the human setting. However, all this optimism was previously seen in the malaria vaccine development field without many real applicable results to date. We describe here the current state-of-the-art in the field of recombinant adenovirus research for malaria vaccine development, in particular referring to their use in combination with other immunogens in heterologous prime-boost protocols, while trying to simultaneously show our contributions and point of view on this subject.
الموضوعات
Animals , Humans , Adenoviridae , Antibodies, Protozoan/immunology , Antigens, Protozoan/immunology , Genetic Vectors , Malaria Vaccines/immunology , Malaria , Vaccines, DNA/immunology , Adenoviridae/immunology , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , T-Lymphocytes/immunology , Vaccines, Subunit/immunologyالملخص
Malaria is a vector-borne disease that is considered to be one of the most serious public health problems due to its high global mortality and morbidity rates. Although multiple strategies for controlling malaria have been used, many have had limited impact due to the appearance and rapid dissemination of mosquito resistance to insecticides, parasite resistance to multiple antimalarial drug, and the lack of sustainability. Individuals in endemic areas that have been permanently exposed to the parasite develop specific immune responses capable of diminishing parasite burden and the clinical manifestations of the disease, including blocking of parasite transmission to the mosquito vector. This is referred to as transmission blocking (TB) immunity (TBI) and is mediated by specific antibodies and other factors ingested during the blood meal that inhibit parasite development in the mosquito. These antibodies recognize proteins expressed on either gametocytes or parasite stages that develop in the mosquito midgut and are considered to be potential malaria vaccine candidates. Although these candidates, collectively called TB vaccines (TBV), would not directly stop malaria from infecting individuals, but would stop transmission from infected person to non-infected person. Here, we review the progress that has been achieved in TBI studies and the development of TBV and we highlight their potential usefulness in areas of low endemicity such as Latin America.
الموضوعات
Animals , Humans , Antibodies, Protozoan/immunology , Antigens, Protozoan/immunology , Malaria Vaccines/immunology , Malaria, Falciparum , Malaria, Vivax , Latin America , Malaria, Falciparum/immunology , Malaria, Falciparum , Malaria, Vivax/immunology , Malaria, Vivax , Plasmodium falciparum/immunology , Plasmodium vivax/immunology , Protozoan Proteins/immunologyالملخص
Insect-borne diseases are responsible for severe mortality and morbidity worldwide. As control of insect vector populations relies primarily on the use of insecticides, the emergence of insecticide resistance as well to unintended consequences of insecticide use pose significant challenges to their continued application. Novel approaches to reduce pathogen transmission by disease vectors are been attempted, including transmission-blocking vaccines (TBVs) thought to be a feasible strategy to reduce pathogen burden in endemic areas. TBVs aim at preventing the transmission of pathogens from infected to uninfected vertebrate host by targeting molecule(s) expressed on the surface of pathogens during their developmental phase within the insect vector or by targeting molecules expressed by the vectors. For pathogen-based molecules, the majority of the TBV candidates selected as well as most of the data available regarding the effectiveness of this approach come from studies using malaria parasites. However, TBV candidates also have been identified from midgut tissues of mosquitoes and sand flies. In spite of the successes achieved in the potential application of TBVs against insect-borne diseases, many significant barriers remain. In this review, many of the TBV strategies against insect-borne pathogens and their respective ramification with regards to the immune response of the vertebrate host are discussed.
الموضوعات
Animals , Humans , Antigens, Protozoan/immunology , Leishmaniasis Vaccines/immunology , Leishmaniasis/prevention & control , Malaria Vaccines/immunology , Malaria/prevention & control , Diptera/immunology , Diptera/parasitology , Insect Vectors/immunology , Insect Vectors/parasitologyالملخص
Recently, we generated two bacterial recombinant proteins expressing 89 amino acids of the C-terminal domain of the Plasmodium vivax merozoite surface protein-1 and the hexa-histidine tag (His6MSP1(19)). One of these recombinant proteins contained also the amino acid sequence of the universal pan allelic T-cell epitope (His6MSP1(19)-PADRE). In the present study, we evaluated the immunogenic properties of these antigens when administered via the intra-nasal route in the presence of distinct adjuvant formulations. We found that C57BL/6 mice immunized with either recombinant proteins in the presence of the adjuvants cholera toxin (CT) or the Escherichia coli heat labile toxin (LT) developed high and long lasting titers of specific serum antibodies. The induced immune responses reached maximum levels after three immunizing doses with a prevailing IgG1 subclass response. In contrast, mice immunized by intranasal route with His6MSP1(19)-PADRE in the presence of the synthetic oligonucleotides adjuvant CpG ODN 1826 developed lower antibody titers but when combined to CT, CpG addition resulted in enhanced IgG responses characterized by lower IgG1 levels. Considering the limitations of antigens formulations that can be used in humans, mucosal adjuvants can be a reliable alternative for the development of new strategies of immunization using recombinant proteins of P. vivax.
الموضوعات
Humans , Animals , Female , Mice , Immunoglobulin G/immunology , Malaria Vaccines/immunology , Malaria, Vivax/immunology , Merozoite Surface Protein 1/immunology , Plasmodium vivax/immunology , Adjuvants, Immunologic , Administration, Intranasal , Immunity, Cellular/immunology , Immunity, Mucosal/drug effects , Immunoglobulin G/blood , Malaria Vaccines/administration & dosage , Malaria, Vivax/prevention & control , Merozoite Surface Protein 1/administration & dosage , Merozoite Surface Protein 1/genetics , Recombinant Proteins/immunology , Vaccines, Synthetic/immunologyالملخص
The thrombospondin related adhesion protein (TRAP) is a malaria pre-erythrocytic antigen currently pursued as malaria vaccine candidate to Plasmodium falciparum. In this study, a long synthetic peptide (LSP) representing a P. vivax TRAP fragment involved in hepatocyte invasion was formulated in both Freund and Montanide ISA 720 adjutants and administered by IM and subcutaneous routes to BALB/c mice and Aotus monkeys. We measured specific humoral immune responses in both animal species and performed a sporozoite challenge in Aotus monkeys to assess the protective efficacy of the vaccine. After immunization both mice and Aotus seroconverted as shown by ELISA, and the specific anti-peptide antibodies cross reacted with the parasite in IFAT assays. Only two out of six immunized animals became infected after P. vivax sporozoite challenge as compared with four out of six animals from the control group. These results suggest that this TRAP fragment has protective potential against P. vivax malaria and deserves further studies as vaccine candidate.
الموضوعات
Animals , Male , Female , Mice , Malaria Vaccines/immunology , Malaria, Vivax/immunology , Plasmodium vivax/immunology , Protozoan Proteins/immunology , Vaccines, Synthetic/immunology , Aotidae , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique, Indirect , Mice, Inbred BALB C , Malaria Vaccines/administration & dosage , Malaria, Vivax/prevention & control , Pilot Projects , Peptide Fragments/immunology , Vaccines, Synthetic/administration & dosageالملخص
The presence of common antigens between Plasmodium falciparum and Anopheles albimanus was demonstrated. Different groups of rabbits were immunized with: crude extract from female An. albimanus (EAaF), red blood cells infected with Plasmodium falciparum (EPfs), and the SPf66 synthetic malaria vaccine. The rabbit's polyclonal antibodies were evaluated by ELISA, Multiple Antigen Blot Assay (MABA), and immunoblotting. All extracts were immunogenic in rabbits according to these three techniques, when they were evaluated against the homologous antigens. Ten molecules were identified in female mosquitoes and also in P. falciparum antigens by the autologous sera. The electrophoretic pattern by SDS-PAGE was different for the three antigens evaluated. Cross-reactions between An. albimanus and P. falciparum were found by ELISA, MABA, and immunoblotting. Anti-P. falciparum and anti-SPf66 antibodies recognized ten and five components in the EAaF crude extract, respectively. Likewise, immune sera against female An. albimanus identified four molecules in the P. falciparum extract antigen. As far as we know, this is the first work that demonstrates shared antigens between anophelines and malaria parasites. This finding could be useful for diagnosis, vaccines, and the study of physiology of the immune response to malaria.
Epítopes de antígenos compartidos entre Plasmodium falciparum y Anopheles albimanus fueron identificados. Diferentes grupos de conejos fueron inmunizados con: extracto crudo de mosquito hembra de An. albimanus (EAaH), glóbulos rojos infectados con P. falciparum (EPfs) y la vacuna antimalárica sintética SPf66. Los anticuerpos policlonales producidos en conejos fueron evaluados por ELISA, inmunoensayo simultáneo de múltiples antígenos (MABA) e Immunoblotting. Todos los extractos resultaron inmunogénicos cuando se evaluaron por ELISA, MABA e Immunoblotting. Diez moléculas fueron identificadas en los mosquitos hembras y diez en los antígenos de P. falciparum por los sueros autólogos. El patrón electroforético por SDS-EGPA fue diferente para los tres antígenos evaluados. La reactividad cruzada de moléculas entre An. albimanus y P. falciparum fue demostrada por ELISA, MABA e Immunoblotting. Anticuerpos anti-P. falciparum y anti-SPf66 reconocieron diez y cinco componentes respectivamente en el extracto crudo de anofelinos (EAaH). Asimismo, sueros inmunes contra An. albimanus hembra identificaron cuatro moléculas en el extracto del antígeno de P. falciparum. Hasta el presente, este es el primer estudio en el que se demuestra la presencia de antígenos compartidos entre anofelinos y los parásitos de malaria. Este hallazgo podría ser de relevancia para el diagnóstico, vacunas e interpretación de la fisiopatología de la respuesta inmunitaria en malaria.
الموضوعات
Animals , Female , Rabbits , Anopheles/immunology , Antibodies, Protozoan/immunology , Antigens, Protozoan/immunology , Epitopes/immunology , Malaria Vaccines/immunology , Plasmodium falciparum/immunology , Antibodies, Protozoan/biosynthesis , Cross Reactions/immunology , Enzyme-Linked Immunosorbent Assay , Host-Parasite Interactions/immunology , Immunoblotting , Immunoenzyme Techniquesالملخص
OBJETIVOS: As vacinas contra o estreptococo B, o herpes-zóster, o HIV, a malária e a dengue, selecionadas por critérios de comercialização iminente ou devido a problemas específicos para sua obtenção, foram objeto de uma revisão sobre o estado atual do seu desenvolvimento. FONTE DOS DADOS:Foi realizada revisão da literatura através da MEDLINE no período de 1996 a 2006, sobre a epidemiologia e imunologia das doenças, analisando tanto os maiores problemas para a obtenção de uma vacina como o estado atual dos estudos, com ênfase para os que estavam em fase mais adiantada. SíNTESE DOS DADOS: Cada uma das cinco doenças escolhidas apresenta problemas específicos para o desenvolvimento de uma vacina. No entanto, a maioria deles já foi ou está em vias de ser resolvido, permitindo prever que uma vacina - ou vacinas - eficaz e segura estará disponível em futuro próximo. CONCLUSÕES:Apesar dos problemas enfrentados para o desenvolvimento dessas vacinas, os avanços da biologia molecular e da imunologia permitiram superar a maioria deles, abrindo a perspectiva para a obtenção de novas vacinas.
الموضوعات
Humans , Acquired Immunodeficiency Syndrome/prevention & control , Dengue/prevention & control , Herpes Zoster/prevention & control , Malaria/prevention & control , Streptococcal Infections/prevention & control , Vaccines/therapeutic use , AIDS Vaccines/immunology , Acquired Immunodeficiency Syndrome/immunology , Clinical Trials as Topic , Dengue Vaccines/immunology , Dengue/immunology , Herpes Zoster Vaccine/immunology , Herpes Zoster/immunology , Malaria Vaccines/immunology , Malaria/immunology , Streptococcal Infections/immunology , Streptococcal Vaccines/immunology , Streptococcus agalactiae/immunology , Vaccines/immunology , Global Healthالملخص
A proteína de superfície de merozoítos-1 (MSP-1) é um dos principais antígenos candidatos à vacina contra a fase assexuada sanguínea da malária. nesta revisäo analisamos dados disponíveis sobre a extensäo da diversidade da MSP-1 em populaçoes naturais de P. falciparum e P. vivax, e o potencial impacto desta diversidade sobre o reconhecimeno imunológico deste antígeno por pacientes com malária. Emfatizamos os dados recentemente obtidos durante estudos realizados na Amazônia brasileira, onde ambas as espécies de parasita säo prevalentes. Os dados moleculares e imunológicos säo discutidos em relaçäo à biologia da populaçäo de parasitas e possíveis estratégias para o desenvolvimento de uma vacina contra a malária baseada na MSP-1.
الموضوعات
Animals , Humans , Antigens, Protozoan/genetics , Plasmodium/genetics , Plasmodium/immunology , Merozoite Surface Protein 1/genetics , Malaria Vaccines/immunology , Alleles , Amino Acid Sequence , Genetic Variation , Malaria/immunology , Plasmodium falciparum/genetics , Plasmodium falciparum/immunology , Plasmodium vivax/genetics , Plasmodium vivax/immunology , Merozoite Surface Protein 1/immunologyالملخص
A malária permanece como a maior causa de morbidade e mortalidade humana em todo o mundo, devido à inexist6encia de medidas de controle eficientes para esta infecçäo. Considera-se que a vacinaçäo pode ser um meio eficaz que complementará outras estratégias de prevençäo e controle desta doença no futuro. Embora a possibilidade de uma vacina contra a malária tenha sido demonstrada nos anos 70, o desenvolvimento de uma facina universalmente eficaz contra esta parasitose tem sido uma difícil tarefa devido a diversos problemas complexos. Um dos aspectos é a complexidade do ciclo de vida do parasita, o qual envolve diferentes estágios que possuem antígenos específicos. Muitos antígenos parasitários têm sido investigados como candidatos potenciais à vacinaçäo, e a busca continua, com antígenos adicionais, sendo recentemente indentificados e caracterizados. Alguns desses antígenos estágio-específicos säo capazes de induzir respostas imunoprotetoras celular e humoral no hospedeiro. Todavia, essas respostas imunoprotetoras säo geralmente restritas geneticamente, adicionando outra dificuldade ao desenvolvimento de uma vacina universalmente eficaz. Por fim, o antígeno estágio-específico deve ser introduzido no hospedeiro utilizando-se um sistema de liberaçäo que possa induzir eficientemente respostas protetoras contra os respectivos estágios. No presente trabalho, revemos as diversas tentativas visando a induçäo de imunidade protetora contra todos os estágios do parasita, levando em consideraçäo os aspectos mencionados acima, que säo os antígenos protetores estágio-específicos, as respostas imunoprotetoras do hospedeiro, e os sistemas de liberaçäo antigênica.
الموضوعات
Humans , Animals , Mice , Malaria/immunology , Malaria/prevention & control , Vaccination , Malaria Vaccines/immunology , Antigens, Protozoan/immunology , Clinical Trials as Topic , Immunity , Life Cycle Stages , Macaca , Plasmodium berghei/immunology , Plasmodium falciparum/immunology , Plasmodium yoelii/immunology , Plasmodium/growth & development , Vaccines, DNA/immunologyالملخص
Malaria remains the most prevalent and devastating parasitic disease worldwide. Vaccination is considered to be an approach that will complement other strategies for prevention and control of the disease in the future. In the last 10 years, intense studies aimed at the development of a malaria vaccine have provided important knowledge of the nature of the host immunological mechanisms of protection and their respective target antigens. It became well established that protective immune responses can be generated against the distinct stages of Plasmodium. However, in general, protective immune responses are directed at stage-specific antigens. The elucidation of the primary structure of these antigens made possible the generation of synthetic and recombinant proteins that are being extensively used in experimental immunizations against the infection. Today, several epitopes of limited polymorphism have been described and protective immunity can be generated by immunization with them. These epitopes are being tested as primary candidates for a subunit vaccine against malaria. Here we critically review the major roadblocks for the development of a malaria vaccine and provide some insight on how these problems are being solved.
الموضوعات
Animals , Humans , Malaria Vaccines , Malaria, Falciparum , Plasmodium falciparum/immunology , Antigens, Protozoan , Immunity , Malaria Vaccines/immunology , Recombinant Proteins , Technology, Pharmaceutical , Vaccines, Syntheticالملخص
El estudio de péptidos antigémicos candidatos al desarrollo de una vacuna contra la malaria por Plasmodium falciparum, ha mostrado la influencia del complejo mayor de histocompatibilidad humano en la respuesta inmune a determinados epítopes parásitarios. El estudio de la asociación entre el Antígeno Leucocitario Humano-B-53 (HLA) y la protección contra malaria severa ha permitido la caracterización de los péptidos presentados por esta molécula definiendo un epítope reconocido por los linfocitos T citotóxicos de los individuos protegidos. A pesar de que existen muchos hallazgos contradictorios, se sugiere la evaluación de este péptido como componente de una vacuna sintética. Otros hallazgos indican que algunas moléculas HLA clase II modifican la respuesta inmune humoral a antígenos parasitarios específicos mostrándose por ejemplo, una asociación positiva entre los portadores del alelo DQw2 y la respuesta de anticuerpos a la secuencia repetitiva (EENV)6 del antígeno Pf155/RESA o una asociación negativa entre los individuos homocigotos al antígeno HLA-DR4 y la respuesta inmune humoral al péptido sintético Spf66. Es importante estudiar los mecanismos por los cuales operan estas asociaciones para definir nuevos péptidos antigénicos potencialmente protectores, verificar el papel de otros genes cuyo locus está ubicado en la región HLA en el desarrollo de susceptibilidad o de resistencia a la infección y aumentar nuestro conocimiento sobre los procesos de selección natural de las moléculas HLA en las poblaciones considerando que el polimorfismo de estas moléculas ha surgido fundamentalmente por el encuentro con diferentes patógenos
الموضوعات
Humans , Major Histocompatibility Complex/drug effects , Major Histocompatibility Complex/immunology , Major Histocompatibility Complex/physiology , Malaria Vaccines/administration & dosage , Malaria Vaccines/antagonists & inhibitors , Malaria Vaccines/genetics , Malaria Vaccines/immunology , Malaria Vaccines/pharmacokinetics , Malaria Vaccines/pharmacology , Malaria Vaccines/standards , Malaria Vaccines/therapeutic useالملخص
This paper describes the study population and the study design of the phase III field trial of the SPf66 vaccine in Brazil. Assessment of validity and precision principles necessary for the appropriate evaluation of the protective effect of the vaccine are discussed, as well as the results of the preliminary analyses of the gathered data. The analytical approach for the estimation of the protective effect of the vaccine is presented. This paper provides the conceptual framework for future publications.
الموضوعات
Humans , Male , Female , Animals , Adult , Adolescent , Child , Middle Aged , Plasmodium falciparum/immunology , Protozoan Proteins/immunology , Malaria Vaccines/immunology , Vaccines, Synthetic/immunology , Brazil/epidemiology , Clinical Trials, Phase III as Topic , Disease Reservoirs , Malaria, Falciparum/mortality , Malaria, Falciparum/prevention & control , Rural Population/statistics & numerical data , Reproducibility of Results , Research Design , Survivorsالملخص
The prevalence of antibodies against the repeat epitope of the circumsporozoite protein (cs) of the standard (PV210) and variant (PVK247) strain of Plasmodium vivax was determined by ELISA in 1170 sera from individual residents of seven localities of the Region Huasteca of San Luis Potosi, Mexico. The capture antigens were the synthetic peptides DDAAD and (ANGAGNQPG)4 that correspond to the repeats of the PV210 and PVK247 cs proteins, respectively. Of the analyzed serum samples, 34.1 percent (400/1170) were positive with one or both of these antigens. Of the sera, 18.2 percent (214/1170) reacted with the DDAADF peptide and 6.6 percent (78/1170) were positive with the variant synthetic peptide. Additionally, 9.2 percent (108/1170) of the samples reacted with both peptides. A sample of 10 percent of positive sera for the variant cs repeat (18/78) was tested with the cs repeat peptide of P. malariae/P. brasilianum (NAAG); almost all of them (16/18, 89 percent) being positive. These results confirm that the transmission of the variant strain of P. vivax is a common Phenomenon in endemic regions in Latin America, as well as in other tropical regions of the world. These findings may have implications for the development of a P. vivax vaccine since that based on the standard cs repeat only would not be universally protective